Table 1. Clinical and YWHAE genotypic description of schizophrenia patients and healthy controls.
| Schizophrenia patients | Controls | Group comparisons | |||
| C allele carriers | G homozygotes | C allele carriers | G homozygotes | ||
| (n = 34) | (n = 38) | (n = 32) | (n = 54) | ||
| Male/female | 14/20 | 25/13 | 19/13 | 26/28 | Chi-square = 3.95, p = 0.27 |
| Age (years) | 27.2±5.9 | 27.9±6.2 | 25.5±6.6 | 27.0±6.6 | F (3,154) = 0.85, p = 0.47 |
| Height (cm) | 162.3±8.7 | 166.4±8.1 | 166.9±9.6 | 164.5±7.4 | F (3,154) = 2.22, p = 0.09 |
| Body weight (kg) | 56.3±9.5 | 62.1±11.6 | 57.9±9.9 | 57.1±9.7 | F (3,154) = 2.48, p = 0.06 |
| Education (years) | 13.9±1.7 | 13.6±2.1 | 16.0±2.2 | 15.9±2.3 | F (3,153 ) = 13.79, p<0.01;Con>Sz |
| Parental education (years) | 13.0±1.8 | 12.4±2.5 | 13.2±2.5 | 13.3±2.4 | F (3,153) = 1.22, p = 0.30 |
| Age of onset (years) | 21.7±4.1 | 23.3±5.1 | - | - | F (1,70) = 2.21, p = 0.14 |
| Duration of illness (years) | 5.4±5.8 | 4.4±4.6 | - | - | F (1,70) = 0.64, p = 0.43 |
| Duration of medication (years) | 2.9±3.9 | 3.2±3.7 | - | - | F (1,70) = 0.11, p = 0.75 |
| Drug dose (haloperidolequivalent, mg/day) | 8.2±7.2 | 9.3±8.3 | - | - | F (1,70) = 0.37, p = 0.55 |
| Total SAPS scorea) | 32.3±26.3 | 28.3±26.6 | - | - | F (1,69) = 0.40, p = 0.53 |
| Total SANS scorea) | 53.1±24.1 | 52.2±20.6 | - | - | F (1,69) = 0.03, p = 0.87 |
| Total gray matter volume (mm3) | 631.3±46.6 | 658.0±64.4 | 655.6±52.3 | 654.5±57.2 | F (3,154) = 1.74, p = 0.16 |
Values represent means ± SDs. Con, controls; SANS, Scale for the Assessment of Negative Sympoms; SAPS, Scale for the Assessment of Positive Symptoms; Sz, schizophrenia.
a)
Data missing for one patient.